Document Detail

Clinical applications of imaging disease burden in multiple sclerosis: MRI and advanced imaging techniques.
MedLine Citation:
PMID:  22364331     Owner:  NLM     Status:  In-Data-Review    
This review will address the critical role of radiographic techniques in monitoring multiple sclerosis disease course and response to therapeutic interventions using conventional imaging. We propose an algorithm of obtaining a contrast-enhanced brain MRI 6 months after starting a disease-modifying therapy, and considering a gadolinium-enhancing lesion on that scan to indicate suboptimal response to therapy. New or enlarging T2 lesions should be followed on scans at 6-month intervals to assess for change, and the presence of one or more enhancing lesions on a 6- or 12-month scan, or two or more new or enlarging T2 lesions on a 12-month scan should prompt consideration of therapy change. New techniques such as PET imaging, magnetic resonance spectroscopy, magnetic resonance relaxometry, iron-sensitive imaging and perfusion MRI will also be overviewed, with their potential roles in monitoring disease course and activity.
Claire Riley; Christina Azevedo; Mary Bailey; Daniel Pelletier
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert review of neurotherapeutics     Volume:  12     ISSN:  1744-8360     ISO Abbreviation:  Expert Rev Neurother     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-02-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101129944     Medline TA:  Expert Rev Neurother     Country:  England    
Other Details:
Languages:  eng     Pagination:  323-33     Citation Subset:  IM    
Yale University School of Medicine, Yale Multiple Sclerosis Center, 40 Temple St LL, New Haven, CT 06510, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Muscle trigger point therapy in tension-type headache.
Next Document:  Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis.